Business context and reporting period
Nova Measuring Instruments Ltd. filed this Form 20-F for the fiscal year ended December 31, 2012; it is an annual report, not a standalone fourth-quarter filing. The Israeli company designs and sells integrated and stand-alone optical metrology systems and related services to the semiconductor industry. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Financial and operating metrics
Amounts are in U.S. dollars; financial statement amounts are in millions unless noted.
| Metric | 2012 | 2011 |
|---|---|---|
| Revenue | $96.2 | $102.8 |
| Gross profit / margin | $51.2 / 53.2% | $58.0 / 56.4% |
| Operating income / margin | $10.6 / 11.0% | $24.7 / 24.0% |
| Net income | $11.8 | $28.1 |
| Diluted EPS | $0.43 | $1.04 |
| Cash from operating activities | $7.7 | $25.1 |
| Cash, cash equivalents and bank deposits | $91.4 | $85.5 |
| Working capital | $106.3 | $94.7 |
| Total assets / shareholders’ equity | $142.0 / $114.8 | $122.9 / $99.9 |
The company reported no significant long-term debt and no off-balance-sheet arrangements. Product revenue was $77.2 million (80% of total); service revenue was $19.0 million. Product gross margin was 58.9% and service gross margin 29.9%. R&D expense, net of grants, was $24.6 million, or 25.6% of revenue.
Material changes versus the prior comparable period
- Revenue fell 6.5%, as product sales declined 9.8% amid weaker industry capital spending in the second half; service revenue rose 9.8% on a larger installed base.
- Gross margin declined 3.2 percentage points. Management attributed lower product margin to fixed costs against lower volume, and lower service margin to higher employee costs.
- Operating income fell about 57%, reflecting lower gross profit and higher operating expenses, particularly R&D, which increased 31.7% to $24.6 million.
- Net income declined to $11.8 million from $28.1 million. The 2011 result included a $2.5 million income tax benefit; 2012 included $0.1 million of tax expense.
- Operating cash flow fell to $7.7 million, with increased receivables and inventory weighing on cash generation. Inventory rose to $17.8 million from $9.6 million, while working capital increased.
- Cash and deposits increased by $4.3 million on management’s broader cash-reserves measure. The balance sheet reports cash and equivalents of $16.0 million, short-term deposits of $75.0 million and long-term deposits of $0.4 million.
Outlook, risks and unusual items
- Management planned higher R&D spending in 2013, approximately $6 million of capital expenditures, and continued investment in new products and customer programs. It cited priorities including foundry ramps at 28nm and 20nm, 3D device metrology, and 450mm wafer development. No specific company revenue or earnings guidance is provided.
- Industry forecasts cited in the filing anticipated 2013 wafer-fab-equipment spending falling roughly 10% (Gartner’s cited estimate was 9.7%). Management expected Nova to outperform the industry, but that expectation is subject to cyclical demand and execution risks.
- Customer concentration is substantial: the largest customer represented 41% of 2012 revenue and the five largest represented 72%. Asia-Pacific excluding Japan accounted for 70% of system installations.
- The company depends significantly on two product lines, semiconductor capital spending, process-equipment partners, a limited supplier base and a single Israeli manufacturing site. Orders may be delayed or cancelled, and quarterly results can fluctuate.
- Inventory write-offs were $1.4 million in 2012; the cash-flow statement also reports a $0.5 million loss related to equipment and inventory damage. The filing describes an approximately $19.8 million contingent royalty liability to Israel’s Office of the Chief Scientist, payable from qualifying future sales, and restrictions on certain grant-funded technology and manufacturing transfers.
- Approximately 98% of cash reserves were held with Israeli banks, with 40% at one institution. Currency movements, regional instability and the cyclical semiconductor market are additional risks. Management and the auditor concluded internal control over financial reporting was effective; the financial-statement audit opinion was unqualified.
Most important facts for investors to verify
- Whether demand, customer orders and the highly concentrated customer mix support the planned 2013 growth and technology-node ramps.
- Whether inventory and receivables convert to sales and cash as expected; inventory nearly doubled during 2012.
- Whether increased R&D and capital spending can restore operating margins after the 2012 decline.
- The terms, future royalty payments and technology-transfer implications of the OCS grants, as well as the company’s cash-bank concentration.
- Whether the cited industry spending forecast and management’s expectation of outperformance remain valid; the filing gives no quantified company guidance.